Form 4 for NERV Minerva Neurosciences, Inc.
Accepted 2023-05-02 00:00:00 ET · period of report 2023-04-28 · accession 0001209191-23-026678 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-02 | 2023-04-28 | NERV | Ahlholm Frederick W | SVP, CFO, Sec | A - Grant | $0.00 | +19.8K | 21.1K | +1,581% | $0 | |
| 2023-05-02 | 2023-05-01 | NERV | Ahlholm Frederick W | SVP, CFO, Sec | S - Sale | $4.48 | -3,580 | 17.5K | -17% | -$16.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-28 | A | A | 19,843 | $0.00 | 21,098 | D | — | — | (F1) Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs"), representing 50% of the shares underlying the PRSUs. On April 28, 2023, the Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for roluperidone. |
| 2 | Common | Common Stock | 2023-05-01 | S | D | 3,580 | $4.48 | 17,518 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.31 to $4.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |